▎Armstrong2025年12月25日,复宏汉霖HLX3901注射液的临床试验申请获得NMPA受理。复宏汉霖围绕底层技术平台做了大量工作,已经建立起TCE三抗、Hanjugator ADC、新靶点新机制HAI Club技术平台。HLX3901正是在TAA/CD3/CD28技术平台上构建,该TCE平台在低T细胞浸润下表现出更优的疗效,同时细胞因子释放更低,达到有效性与安全性的更优平衡。在临床前...
Source Link▎Armstrong2025年12月25日,复宏汉霖HLX3901注射液的临床试验申请获得NMPA受理。复宏汉霖围绕底层技术平台做了大量工作,已经建立起TCE三抗、Hanjugator ADC、新靶点新机制HAI Club技术平台。HLX3901正是在TAA/CD3/CD28技术平台上构建,该TCE平台在低T细胞浸润下表现出更优的疗效,同时细胞因子释放更低,达到有效性与安全性的更优平衡。在临床前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.